Clinical trials: Psilocybin
Depressive Disorder, Depressive Disorder, Treatment-Resistant
Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression
The study hypothesis is that the antidepressant effect of psilocybin is mediated by a normalization of the functioning of the positive valence system.
- Conditions
- Depressive Disorder, Depressive Disorder, Treatment-Resistant, Hallucinogens, Reinforcement, Psychology
- Trial name
- PSILODAC (NCT06650800)
- Testing
- Psilocybin, MRI
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Mental Health
Mindfulness-Assisted Psychedelic Therapy
The goal of this clinical trial is to test psilocybin in combination with mindfulness training in healthy adults. The main question it aims to answer is "Does mindfulness training enhance the effects of psychedelic therapy…
- Trial name
- MAPT (NCT06233344)
- Testing
- Psilocybin plus mindfulness training, Psilocybin
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Depressive Symptoms, Anxiety
Psychopharmacology of Psilocybin in Cancer Patients
This research is being done to study the psychological effects of psilocybin in cancer patients. Psilocybin is a naturally occurring substance found in some mushrooms that some cultures have used for centuries in religious…
- Conditions
- Depressive Symptoms, Anxiety, Cancer
- Trial name
- NCT00465595
- Testing
- psilocybin
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Johns Hopkins University
Demoralization
Pragmatic Trial of Psilocybin Therapy in Palliative Care
This multicenter, triple-blind, phase 2, randomized controlled trial will evaluate the efficacy and safety of psilocybin therapy compared to an active control in treating demoralization in adults near the end of life (≤2 years…
- Trial name
- PT2PC (NCT05403086)
- Testing
- Psilocybin, Ketamine
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- Charles S. Grob, M.D.
Amyotrophic Lateral Sclerosis
Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis
This study aims to study the feasibility of psilocybin therapy for patients with Amyotropic Lateral Sclerosis (ALS) with depressed mood.
- Trial name
- NCT06656702
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Johns Hopkins University
PTSD
Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder
This study is a community-informed, pragmatic, open-label, phase 1 clinical trial of group-format psilocybin-assisted therapy (GPAT) for individuals with post-traumatic stress disorder (PTSD).
- Trial name
- GPAT (NCT07506395)
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of New Mexico
Advanced Cancer
Psilocybin Therapy in Advanced Cancer
The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose niacin 100mg) in the treatment of anxiety, depression, and existential distress (i.e., loss of…
- Trial name
- NCT05398484
- Testing
- Psilocybin 25 mgs, Niacin 100mg, Psychotherapy
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- NYU Langone Health
Anorexia Nervosa
Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young Adults With Anorexia Nervosa
The goal of this clinical trial is to learn if psilocybin, given with psychological support, is safe and helps treat anorexia nervosa in young adults.
- Trial name
- psiAN (NCT07169747)
- Testing
- Psilocybin
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Region Skane
Stroke, Chronic Stroke
Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability
The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke.
- Conditions
- Stroke, Chronic Stroke, Intracerebral Haemorrhage, Intracerebral Haemorrhage (ICH)
- Trial name
- PHATHOM (NCT07053917)
- Testing
- Psilocybin (Usona Institute)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Borderline Personality Disorder, Major Depressive Disorder
Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder
The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).
- Trial name
- NCT05399498
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Chicago
Opioid Dependence, Chronic Pain
Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication
This is an open-label pilot trial to assess the safety and feasibility of a novel 8-week psilocybin-assisted psychotherapy intervention to facilitate successful tapering/discontinuation of opioid pain medication in adult patients…
- Trial name
- NCT05585229
- Testing
- Psilocybin-assisted Psychotherapy
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University of British Columbia
Methamphetamine Use Disorder
Psilocybin for Methamphetamine Addiction
The primary purpose of this study is to preliminarily determine if the use of psilocybin to promote abstinence from methamphetamine is feasible and well tolerated in populations such as those found in Northern Louisiana.
- Trial name
- NCT06899594
- Testing
- Psilocybin 25 mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Kevin Murnane
Bipolar II Disorder
Psilocybin Therapy for Depression in Bipolar II Disorder
The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy in people with Bipolar II Disorder.
- Trial name
- BAP (NCT05065294)
- Testing
- Psilocybin therapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, San Francisco
Treatment Resistant Depression
Psilocybin in Depression Resistant to Standard Treatments
A single centre clinical trial to evaluate the feasibility, safety and efficacy of psilocybin, given under supportive conditions, in a randomised, blinded design in adult participants with treatment resistant major depressive…
- Trial name
- PsiDeR (NCT04959253)
- Testing
- Psilocybin assisted therapy
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- King's College London
Anhedonia in Healthy Volunteers, Older Adults (50-90 Years)
A Study of Psychedelics in Healthy Older Adults With Low Well-being
This study is being conducted to understand changes in brain activity following administration of two different drugs (Psilocybin and Dextromethorphan) in older adults with low well-being.
- Trial name
- OAD1 (NCT07386730)
- Testing
- Psilocybin (drug), Dextromethorphan (DXM)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Jennifer Mitchell
Major Depression
Study of Psilocybin Under Anesthesia Controlled by EEG
Major depressive disorder (MDD) affects millions of Americans and remains difficult to treat. Psilocybin, a psychedelic compound, has shown promise for reducing depression symptoms, but a key challenge in psychedelic research is…
- Trial name
- SPACE (NCT07479550)
- Testing
- Psilocybin (Usona Institute), Propofol
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Major Depressive Disorder
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.
- Trial name
- APPROACH (NCT06564818)
- Testing
- CYB003, Psychological Support
- Where
- 45 sites in United States
- Volunteers
- 223 people
- Sponsor
- Cybin IRL Limited
Depressive Disorder, Major
Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms
This is a randomised double-blind clinical trial. The aim is to compare the efficacy and mechanisms of action of psilocybin, the primary psychoactive substance in 'magic mushrooms', with the selective serotonin reuptake inhibitor…
- Trial name
- Psilodep-RCT (NCT03429075)
- Testing
- Psilocybin + Escitalopram
- Where
- United Kingdom
- Volunteers
- 59 people
- Sponsor
- Imperial College London
Psychedelic Effects in Healthy Volunteers
Psilocybin Administration With 5-HT1a Blockade
The purpose of this study is to assess the effects of 5-HT1A receptor blockade on the acute subjective effects of psilocybin, as measured through subjective survey measures and acute electroencephalography (EEG).
- Trial name
- PsilBlock1 (NCT07565493)
- Testing
- Pindolol, Psilocybin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Alcohol Use Disorder
Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder
This study aims to determine the safety and preliminary efficacy of psilocybin-assisted psychotherapy in improving alcohol-related outcomes among adults with severe alcohol use disorder in a a double-blind, dose-comparison…
- Trial name
- NCT07296094
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Brigham and Women's Hospital